AOD-9604 Moderate Evidence

What It Is

AOD-9604 is a 16-amino-acid synthetic peptide with the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with a disulfide bond between the two cysteine residues), corresponding to the C-terminal domain of human growth hormone (hGH residues 176-191) plus an added N-terminal tyrosine to stabilize the synthetic peptide against aminopeptidase degradation. The fragment was designed to isolate the lipolytic activity of full-length hGH from its growth-promoting and insulin-antagonistic effects, which are mediated by different regions of the 191-amino-acid hGH molecule.

AOD-9604 was developed by Professor Frank Ng and colleagues at Monash University in Melbourne, Australia, during the 1990s, and licensed to Metabolic Pharmaceuticals Ltd (publicly listed on the Australian Securities Exchange). Metabolic advanced the compound through extensive preclinical development and six completed randomized double-blind placebo-controlled clinical trials totaling more than 900 subjects before terminating the primary obesity program in 2007 after the Phase 2b OPTIONS study failed to demonstrate statistically significant weight loss at 24 weeks. Subsequent development rights have moved through several licensing arrangements; as of April 2026 AOD-9604 remains investigational.

The compound has been studied via both oral and parenteral (SubQ / intraperitoneal in animals) administration. The original Metabolic Pharmaceuticals clinical program was predominantly oral (tablets), leveraging the relatively robust gastrointestinal stability of the 16-amino-acid fragment with disulfide-bond constraint. Community community use has largely shifted to SubQ administration, following conventional peptide-research practice.

AOD-9604 holds a unique regulatory position: it is not FDA-approved for any indication in the United States, not approved by the EMA, but has received a "Self-Affirmed GRAS" (Generally Recognized As Safe) determination for dietary-supplement use by independent toxicology review commissioned by marketers, and is notified with Australia's Therapeutic Goods Administration (TGA) as a cosmetic ingredient. These non-drug regulatory pathways have supported a legitimate if narrow cosmetic and compounding-pharmacy supply in several jurisdictions — distinct from the research-chemical gray market where most peptides in this space reside.

Mechanism of Action

AOD-9604's mechanism is distinctively well-characterized for a research peptide, owing to Frank Ng's systematic mechanistic work leading up to the clinical program:

• β3-adrenergic receptor-mediated lipolysis — AOD-9604 engages β3-adrenergic receptor signaling in adipocytes, driving cyclic AMP elevation, hormone-sensitive lipase activation, and mobilization of stored triglycerides as free fatty acids and glycerol. Heffernan et al. demonstrated that β3-AR knockout mice show substantially attenuated AOD-9604 response, confirming the receptor-level mechanism. Ng et al. (Endocrinology 2000; 2002) systematically characterized the receptor pharmacology.
• Does NOT bind the hGH receptor — The defining mechanistic feature. In in-vitro hGH receptor-binding assays and downstream STAT5 phosphorylation assays, AOD-9604 shows no measurable receptor engagement (Ng FM et al., PMID 11673763). This is why AOD-9604 does not elevate IGF-1 and does not produce hGH's signature metabolic effects (glucose intolerance, sodium retention, carpal tunnel, acromegalic changes).
• Increased fat oxidation — In obese and lean mice, AOD-9604 administration increases in-vivo fat oxidation measured by indirect calorimetry (RQ reduction, increased fat-derived oxygen consumption). Elevated plasma glycerol (lipolysis marker) supports the mobilization mechanism.
• Anti-lipogenesis — Reduces acetyl-CoA carboxylase activity and triglyceride synthesis in adipocytes, providing a secondary mechanism limiting fat accumulation beyond primary lipolytic effect.
• Cartilage-repair activity (secondary interest) — Subsequent in-vitro and in-vivo work identified AOD-9604 activity on chondrocyte proliferation and cartilage matrix synthesis (chondroitin sulfate, collagen type II), driving post-obesity-program interest in osteoarthritis and cartilage-repair applications. Mechanism in cartilage involves pathways partially distinct from the β3-AR-lipolysis axis in adipose.
• Normal glycemic effect — Unlike hGH, AOD-9604 does not impair glucose tolerance or reduce insulin secretion. Glucose and insulin levels remain stable on chronic administration, an important safety-profile feature that distinguishes it from full-length hGH therapy.
• Clearance — Rapid degradation in biological systems via sequential amino-terminal truncation by aminopeptidases. The N-terminal tyrosine modification extends half-life vs native hGH(176-191) but does not produce the extended half-life of acylated or pegylated peptides. Plasma half-life is approximately 15–30 minutes after parenteral administration.
• Oral bioavailability — Moderate oral bioavailability was demonstrated in the Metabolic Pharmaceuticals clinical program — sufficient for the 1 mg/day oral dosing that produced the Phase 2 weight-loss signal, though absolute bioavailability has not been publicly quantified.

What the Research Shows

AOD-9604's research database is unusually structured around a formal pharmaceutical development program rather than an academic curiosity, producing a cleaner evidence base than most "research peptides":

• Preclinical lipolysis and weight loss in obese mice — Ng FM, Sun J, Sharma L et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Established the lipolytic activity in ob/ob and Zucker rat obesity models without the untoward hGH metabolic effects.
• Heffernan M et al. hGH / AOD9604 lipid metabolism in obese and β3-AR KO mice — Demonstrated that β3-adrenergic receptor knockout mice show substantially attenuated AOD-9604 response, establishing β3-AR as a primary mediator.
• PMID 11673763 — Ng FM et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment — Both hGH and AOD-9604 reduce body weight in obese mice with increased in-vivo fat oxidation and elevated plasma glycerol; AOD-9604 did NOT induce hyperglycemia or reduce insulin secretion — the defining divergence from full-length hGH. AOD-9604 does not interact with the hGH receptor, confirming the "fragment pro-hormone" hypothesis.
• Phase 1 human safety and PK — Single-ascending-dose and multi-dose human studies confirmed acceptable safety and oral absorption. Broad safety margin supported subsequent Phase 2 development.
• Phase 2 12-week RCT — 71 obese adults randomized to 0.25, 0.5, 1 mg/day oral AOD-9604 or placebo × 12 weeks. 34 subjects receiving 1 mg/day lost 2.6 kg vs 0.8 kg placebo (37 subjects) — statistically significant at 1 mg dose. Improvement in glucose tolerance also noted. Safety comparable to placebo.
• Phase 2b OPTIONS study (2007) — 536-subject, 24-week RCT at doses of 0, 0.25, 0.5, and 1 mg/day oral AOD-9604. Primary endpoint was weight loss over 24 weeks of treatment. The trial failed — weight loss at 24 weeks did not reach statistical significance vs placebo at any dose, although a trend toward modest weight loss continued. Metabolic Pharmaceuticals announced termination of the AOD-9604 obesity program after these results.
• Post-obesity-program development — Following the Phase 2b failure, Metabolic Pharmaceuticals pivoted toward cartilage and osteoarthritis applications, based on observed chondroprotective effects in animal models. Phase 2 osteoarthritis-of-the-knee studies reported modest efficacy signals; the program has not advanced to Phase 3 approval as of April 2026.
• Cosmetic-ingredient development — AOD-9604 is marketed in topical skincare formulations in Australia and several other jurisdictions as a cosmetic anti-aging ingredient. Evidence base for topical skin applications is minimal and largely consists of manufacturer in-vivo consumer-perception studies rather than published peer-reviewed trials.
• Safety review — A safety review in the Journal of Obesity & Food Metabolism aggregated the six randomized double-blind placebo-controlled trials (>900 subjects total) evaluating AOD-9604 across oral and other routes. Conclusion: acceptable safety profile, few adverse events beyond placebo, no evidence of metabolic disruption or hGH-receptor-mediated effects. This is an unusually clean safety database for a "research peptide."
• Comparison to GLP-1 agonists — Modern GLP-1 obesity therapeutics (semaglutide / Wegovy 2021, tirzepatide / Zepbound 2023) produce 12–22% weight loss in Phase 3 obesity trials. AOD-9604's best-case ~3% weight loss at 12 weeks (Phase 2) does not compete in the modern obesity pharmacotherapy landscape. Its relevance is narrower: a benign-safety-profile adjunct for body composition, not a primary obesity treatment.

Human Data

AOD-9604 has one of the more extensive controlled human databases of any research peptide on this site — a direct consequence of having completed a formal pharmaceutical development program:

• Six completed RCTs totaling >900 subjects — Phase 1 and Phase 2 studies across oral and parenteral dosing, short-term (weeks) and long-term (24 weeks) treatment duration.
• Phase 1 safety / PK studies — Dose-ascending studies in healthy volunteers established acceptable single-dose and multi-dose safety; oral bioavailability sufficient for therapeutic dosing at 0.25–1 mg/day; plasma half-life approximately 15–30 minutes post-oral dose; no dose-limiting toxicity observed at doses up to several-fold above the eventual therapeutic dose.
• Phase 2 12-week weight-loss trial — 71 obese adults randomized to 0.25, 0.5, or 1 mg/day oral AOD-9604 or placebo × 12 weeks. 1 mg dose arm (n=34) achieved 2.6 kg weight loss vs 0.8 kg placebo (n=37) — statistically significant. Glucose tolerance also improved on AOD-9604.
• Phase 2b OPTIONS study (2007) — 536-subject, 24-week, 4-arm (placebo, 0.25, 0.5, 1 mg/day oral) RCT. Failed primary endpoint — weight loss at 24 weeks did not reach statistical significance vs placebo. Development terminated.
• Phase 2 osteoarthritis of the knee — Subsequent post-obesity-program Phase 2 studies in OA reported modest symptom-and-structure signals with topical and intra-articular AOD-9604, although full trial details have not been fully published in peer-reviewed form.
• Cosmetic / topical skin studies — Manufacturer consumer-perception in-vivo studies for cosmetic applications; not peer-reviewed dermatology research.
• FDA PCAC "Saving AOD9604" submission (Dec 2024) — Edwin Lee MD submitted a presentation to the FDA Pharmacy Compounding Advisory Committee arguing for AOD9604 compounding eligibility, citing the safety database and mechanistic differentiation from full hGH.
• No published data for SubQ community-typical doses — The clinical program was predominantly oral at 0.25–1 mg/day. Community SubQ use at 250–500 mcg/day is a different formulation and route without controlled human data at that protocol.

Dosing from the Literature

AOD-9604 clinical dosing is anchored to the Metabolic Pharmaceuticals Phase 2/2b program. Community SubQ dosing extrapolates loosely from the oral clinical doses.

Reconstitution & Storage

AOD-9604 is supplied for research use as a lyophilized peptide:

• Reconstitution — For a 2 mg lyophilized vial, add 1 mL BAC water for a 2,000 mcg/mL concentration; 500 mcg dose = 0.25 mL (25 units on a U-100 insulin syringe).
• Stability — The disulfide bond between the two cysteines can undergo reduction under prolonged storage; keep reconstituted solution cold and use within 28 days.
• Storage — Lyophilized vials stable at −20°C for 2+ years; refrigerated reconstituted solution for up to 28 days. Do not freeze reconstituted product.
• Inspection — Clear, colorless reconstituted solution. Discard if cloudy, discolored, or showing visible particulate.

→ Use the Kalios Dosing Calculator for vial conversions

Side Effects & Risks

AOD-9604 has one of the cleanest safety profiles in this category, drawn from the extensive Metabolic Pharmaceuticals clinical database:

• Overall tolerability — Across six RCTs totaling >900 subjects, AOD-9604 demonstrated safety comparable to placebo. No dose-limiting adverse effects at doses up to 1 mg/day oral.
• Mild gastrointestinal effects — Mild nausea, occasional dyspepsia. Generally self-limiting.
• Injection-site reactions (SubQ) — Mild redness, tenderness at injection site. Uncommon and self-limiting.
• No glucose intolerance — Unlike full hGH, AOD-9604 does not impair glucose tolerance. This is a key safety differentiator.
• No IGF-1 elevation — AOD-9604 does not activate the hGH receptor; IGF-1 does not rise with chronic administration. This eliminates the theoretical cancer-promotion concern of elevated IGF-1 associated with hGH therapy.
• No hGH-like side effects — No carpal tunnel syndrome, no sodium retention, no edema, no arthralgia, no acromegalic changes. These full-hGH side effects are absent with AOD-9604 due to the non-receptor-mediated mechanism.
• Pregnancy and lactation — Not studied; avoid.
• Pediatric — Not studied; not appropriate for use in children.
• Drug interactions — Minimal characterized interactions. β-adrenergic receptor antagonists (propranolol, metoprolol) could theoretically attenuate the β3-AR-mediated lipolytic effect; not clinically confirmed.
• Sourcing / purity — As a research-only synthetic peptide, AOD-9604 quality varies between vendors. Independent third-party Certificate of Analysis (HPLC purity ≥98%, mass-spec confirmation including disulfide bond integrity) is essential.
• WADA — AOD-9604 is not specifically named on the WADA Prohibited List. Athletes should consult their sport-specific federation; as an hGH-fragment with documented non-hGH-receptor mechanism, it does not have a clean fit under S2 peptide hormones or growth factors categories but could plausibly be interpreted under broader rubrics.

Bloodwork & Monitoring

Limited monitoring requirements given the clean safety profile. For research awareness:

• Baseline CMP and CBC — Standard pre-treatment chemistry.
• Fasting glucose and HbA1c — Baseline and mid-cycle. AOD-9604 should NOT impair glycemic control; rising glucose or HbA1c would be unexpected and warrants evaluation.
• IGF-1 — Baseline. AOD-9604 should NOT raise IGF-1; elevation would indicate off-target hGH-receptor engagement (possibly reflecting product impurity with full-length hGH contamination) and warrants investigation.
• Thyroid panel — Baseline. No documented thyroid effects but standard baseline.
• Body composition — DEXA scan at baseline and post-cycle for objective body-composition tracking (fat mass, lean mass).
• Lipid panel — Baseline and mid-cycle. Lipolysis produces transient increases in circulating free fatty acids; chronic effect on lipid profile is generally neutral in published data.

Commonly Stacked With

Community stacking with AOD-9604 is anecdotal; no clinical combination data exists.

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

What AOD-9604 users end up weighing against it:

Next Steps

Key References

1. Ng FM, Sun J, Sharma L, Libinaki R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID: 11044801. (Foundational mechanistic characterization.)
2. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID: 11713213. (β3-AR knockout dependence.)
3. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. PMID: 10950816.
4. Ng FM, Sun J, Adamafio NA, Spiteri J, Farag FM, Belot J, Morris HR. Stability and solution properties of a synthetic C-terminal lipolytic domain of human growth hormone (AOD9604). Proc Aust Soc Med Res. 1999;32:97-105.
5. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1586-1592. PMID: 11673763. (Both hGH and AOD-9604 reduce body weight; AOD does not interact with hGH receptor or produce glucose intolerance.)
6. Metabolic Pharmaceuticals Ltd. Phase 2 OBESITY clinical trial results: AOD9604 12-week dose-ranging study in obese adults (0.25, 0.5, 1 mg/day). 2004-2005. (Positive Phase 2 signal at 1 mg/day: 2.6 kg weight loss vs 0.8 kg placebo.)
7. Metabolic Pharmaceuticals Ltd. Phase 2b OPTIONS clinical trial results: AOD9604 24-week randomized placebo-controlled trial in 536 obese adults. 2007. (Failed primary endpoint. Publicly disclosed in biotech press; led to obesity program termination.)
8. The effect of AOD9604 on weight loss in obese adults: Results of a randomized, double-blind, placebo-controlled, multicenter study (referenced in Chugh 2012 review).
9. Chugh PK, Sharma S. Recent advances in the pathophysiology and pharmacological treatment of obesity. J Clin Pharm Ther. 2012;37(5):525-535. DOI: 10.1111/j.1365-2710.2012.01347.x. (Places AOD-9604 in obesity-pharmacotherapy context.)
10. Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014;95(1):53-66. PMID: 24105257. (Obesity pharmacotherapy review discussing AOD-9604's Phase 2b failure.)
11. Kasim-Karakas SE, Cunningham WM, Tsodikov A. Relation of nutrients and hormones in polycystic ovary syndrome. Obesity Pharmacotherapy: Current Perspectives and Future Directions. 2013. PMC: PMC3584306. (Review describing AOD-9604 Phase 2 results and 2007 program termination.)
12. Safety review in the Journal of Obesity & Food Metabolism aggregating six RCTs of AOD-9604 (>900 subjects). (Comprehensive safety database summary.)
13. Wood A. AOD-9604 as a potential candidate therapeutic for osteoarthritis. Cartilage research workshop presentation 2012. (Post-obesity-program pivot toward cartilage repair.)
14. Lee E. "Saving AOD9604" — FDA Pharmacy Compounding Advisory Committee meeting submission, December 4, 2024. (Advocacy presentation for AOD9604 compounding reclassification.)
15. US FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2). fda.gov. (AOD-9604 is listed on Category 2.)
16. Therapeutic Goods Administration (Australia). AOD-9604 cosmetic ingredient notification. tga.gov.au. (Australian regulatory context.)
17. ClinicalTrials.gov. Metabolic Pharmaceuticals AOD9604 Phase 2 / Phase 2b obesity trials registration and results. clinicaltrials.gov. (Trial documentation.)
18. WADA. The 2026 Prohibited List. World Anti-Doping Agency. wada-ama.org. (AOD-9604 not specifically named.)
19. Greenway FL, de Jonge L, Blanchard D, Frisard M, Smith SR. Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition. Obes Res. 2004;12(7):1152-1157. (Background context for lipolytic obesity-supplement landscape that AOD-9604 competes within.)
20. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. PMID: 26132939. (Comparator: GLP-1 agonist obesity therapeutic evidence — the modern standard AOD-9604 fails to meet.)